{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:11:44Z","timestamp":1793193104386,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N9301900065"],"award-info":[{"award-number":["75N9301900065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00016"],"award-info":[{"award-number":["75N93021C00016"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N9301900065"],"award-info":[{"award-number":["75N9301900065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/PR40401\/BIOBANK\/03.2020"],"award-info":[{"award-number":["BT\/PR40401\/BIOBANK\/03.2020"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/PR30223\/MED\/2018"],"award-info":[{"award-number":["BT\/PR30223\/MED\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"DST | Science and Engineering Research Board","doi-asserted-by":"publisher","award":["IPA\/2020\/000077"],"award-info":[{"award-number":["IPA\/2020\/000077"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-022-01161-5","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T06:02:59Z","timestamp":1654754579000},"page":"974-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Inactivated whole-virion vaccine BBV152\/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern"],"prefix":"10.1038","volume":"7","author":[{"given":"Rajesh","family":"Vikkurthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgar","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-0237","authenticated-orcid":false,"given":"Anupama R.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Someshwar Nath","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Sachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvechchha","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Nikam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal Prasad","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal Ahmad","family":"Parray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Kshetrapal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Coshic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9195-2730","authenticated-orcid":false,"given":"Ramachandran","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-5966","authenticated-orcid":false,"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7013-2250","authenticated-orcid":false,"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjini","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-8448","authenticated-orcid":false,"given":"Nimesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"1161_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis. 21, 950\u2013961 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1161_CR2","doi-asserted-by":"publisher","unstructured":"Ella, R. et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(21)02000-6 (2021).","DOI":"10.1016\/S0140-6736(21)02000-6"},{"key":"1161_CR3","doi-asserted-by":"publisher","first-page":"636768","DOI":"10.3389\/fimmu.2021.636768","volume":"12","author":"A Ansari","year":"2021","unstructured":"Ansari, A. et al. Immune memory in mild COVID-19 patients and unexposed donors reveals persistent T cell responses after SARS-CoV-2 infection. Front. Immunol. 12, 636768 (2021).","journal-title":"Front. Immunol."},{"key":"1161_CR4","doi-asserted-by":"publisher","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"1161_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41590-021-00902-8","volume":"22","author":"J Zuo","year":"2021","unstructured":"Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 22, 620\u2013626 (2021).","journal-title":"Nat. Immunol."},{"key":"1161_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"1161_CR7","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e15 (2020).","journal-title":"Cell"},{"key":"1161_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168.e14 (2020).","journal-title":"Cell"},{"key":"1161_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274 (2020).","journal-title":"Nature"},{"key":"1161_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e19 (2020).","journal-title":"Cell"},{"key":"1161_CR11","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).","journal-title":"Cell Rep."},{"key":"1161_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.immuni.2021.01.008","volume":"54","author":"A Bonifacius","year":"2021","unstructured":"Bonifacius, A. et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity 54, 340\u2013354.e6 (2021).","journal-title":"Immunity"},{"key":"1161_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","volume":"595","author":"JS Turner","year":"2021","unstructured":"Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 595, 421\u2013425 (2021).","journal-title":"Nature"},{"key":"1161_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2021.04.003","volume":"2","author":"S Kalimuddin","year":"2021","unstructured":"Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med 2, 682\u2013688.e4 (2021).","journal-title":"Med"},{"key":"1161_CR15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1161_CR16","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 Variant. N. Engl. J. Med. 384, 1885\u20131898 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1161_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1126\/science.abg7404","volume":"371","author":"DM Altmann","year":"2021","unstructured":"Altmann, D. M., Boyton, R. J. & Beale, R. Immunity to SARS-CoV-2 variants of concern. Science 371, 1103\u20131104 (2021).","journal-title":"Science"},{"key":"1161_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1473-3099(21)00680-0","volume":"22","author":"R Thiruvengadam","year":"2021","unstructured":"Thiruvengadam, R. et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 22, 473\u2013482 (2021).","journal-title":"Lancet Infect Dis."},{"key":"1161_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637\u2013646 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1161_CR20","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 \u2013 preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1161_CR21","doi-asserted-by":"publisher","first-page":"e106267","DOI":"10.15252\/embj.2020106267","volume":"39","author":"J Buchrieser","year":"2020","unstructured":"Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).","journal-title":"EMBO J."},{"key":"1161_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1161_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"1161_CR24","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","volume":"397","author":"EC Wall","year":"2021","unstructured":"Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331\u20132333 (2021).","journal-title":"Lancet"},{"key":"1161_CR25","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220\u20134236 e4213 (2021).","journal-title":"Cell"},{"key":"1161_CR26","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361.e6 (2021).","journal-title":"Cell"},{"key":"1161_CR27","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","volume":"54","author":"F Muecksch","year":"2021","unstructured":"Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853\u20131868 e1857 (2021).","journal-title":"Immunity"},{"key":"1161_CR28","doi-asserted-by":"publisher","unstructured":"Cho, A. et al. Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination. Nature https:\/\/doi.org\/10.1038\/s41586-021-04060-7 (2021).","DOI":"10.1038\/s41586-021-04060-7"},{"key":"1161_CR29","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf1555 (2021).","DOI":"10.1126\/scitranslmed.abf1555"},{"key":"1161_CR30","doi-asserted-by":"publisher","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd2223 (2021).","DOI":"10.1126\/scitranslmed.abd2223"},{"key":"1161_CR31","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","volume":"2","author":"A Tarke","year":"2021","unstructured":"Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2, 100355 (2021).","journal-title":"Cell Rep. Med."},{"key":"1161_CR32","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Invest."},{"key":"1161_CR33","doi-asserted-by":"publisher","unstructured":"Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abd2071 (2020).","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"1161_CR34","doi-asserted-by":"publisher","first-page":"eabj9853","DOI":"10.1126\/science.abj9853","volume":"374","author":"J Mateus","year":"2021","unstructured":"Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science 374, eabj9853 (2021).","journal-title":"Science"},{"key":"1161_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"1161_CR36","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1084\/jem.20052433","volume":"203","author":"U Wille-Reece","year":"2006","unstructured":"Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249\u20131258 (2006).","journal-title":"J. Exp. Med."},{"key":"1161_CR37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843\u2013850 (2007).","journal-title":"Nat. Med."},{"key":"1161_CR38","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","volume":"2","author":"KW Cohen","year":"2021","unstructured":"Cohen, K. W. et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2, 100354 (2021).","journal-title":"Cell Rep. Med."},{"key":"1161_CR39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745\u2013763 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"1161_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529\u2013542 (2014).","journal-title":"Immunity"},{"key":"1161_CR41","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428\u20131434 (2020).","journal-title":"Nat. Med."},{"key":"1161_CR42","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","volume":"54","author":"MM Painter","year":"2021","unstructured":"Painter, M. M. et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity 54, 2133\u20132142.e3 (2021).","journal-title":"Immunity"},{"key":"1161_CR43","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"1161_CR44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.it.2014.06.002","volume":"35","author":"N Schmitt","year":"2014","unstructured":"Schmitt, N., Bentebibel, S. E. & Ueno, H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol. 35, 436\u2013442 (2014).","journal-title":"Trends Immunol."},{"key":"1161_CR45","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"1161_CR46","doi-asserted-by":"publisher","unstructured":"Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abd7114 (2020).","DOI":"10.1126\/sciimmunol.abd7114"},{"key":"1161_CR47","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2012.11.020","volume":"38","author":"D Baumjohann","year":"2013","unstructured":"Baumjohann, D. et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38, 596\u2013605 (2013).","journal-title":"Immunity"},{"key":"1161_CR48","doi-asserted-by":"publisher","unstructured":"Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abl9105 (2021).","DOI":"10.1126\/sciimmunol.abl9105"},{"key":"1161_CR49","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","volume":"39","author":"M Locci","year":"2013","unstructured":"Locci, M. et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 758\u2013769 (2013).","journal-title":"Immunity"},{"key":"1161_CR50","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita, R. et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34, 108\u2013121 (2011).","journal-title":"Immunity"},{"key":"1161_CR51","doi-asserted-by":"publisher","unstructured":"Ansari, A. et al. An efficient immunoassay for the B-cell help function of SARS-CoV-2 specific memory CD4+ T cells. Cell Rep. Methods https:\/\/doi.org\/10.1016\/j.crmeth.2022.100224 (2022).","DOI":"10.1016\/j.crmeth.2022.100224"},{"key":"1161_CR52","doi-asserted-by":"publisher","first-page":"641447","DOI":"10.3389\/fimmu.2021.641447","volume":"12","author":"T Shrivastava","year":"2021","unstructured":"Shrivastava, T. et al. Comparative immunomodulatory evaluation of the receptor binding domain of the SARS-CoV-2 spike protein; a potential vaccine candidate which imparts potent humoral and Th1 type immune response in a mouse model. Front. Immunol. 12, 641447 (2021).","journal-title":"Front. Immunol."},{"key":"1161_CR53","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.gendis.2020.07.006","volume":"7","author":"J Hu","year":"2020","unstructured":"Hu, J. et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 7, 551\u2013557 (2020).","journal-title":"Genes Dis."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01161-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:50:18Z","timestamp":1669283418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01161-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["1161"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01161-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.14.21266294","asserted-by":"object"}]},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"27 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.G. and A.A. are listed as inventors on Indian patent application no. 202111003148 filed in 2021 (submitted by NII) that covers the use of \u2018T-cell qualitative immunoassay\u2019 for vaccine evaluation. A. Sette is consultant for GritstoneBio, FlowPharma, ArcturusTherapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. LJI has filed USA patent protection for various aspects of T-cell epitope and vaccine design work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}